Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kairos Pharma, Ltd. Common Stock (NY: KAPA )

0.9550 -0.0650 (-6.37%)
Official Closing Price Updated: 4:10 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 53,822
Open 0.9900
Bid (Size) 0.9010 (12)
Ask (Size) 0.9980 (1)
Prev. Close 1.020
Today's Range 0.9151 - 1.040
52wk Range 0.8506 - 4.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Presents Positive Preclinical Data on KROS 101 and KROS 401 at AACR IO Conference
Via Investor Brand Network
Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds’ Potential as Therapeutics for Melanoma and Glioblastoma
From Kairos Pharma, Ltd
Via Business Wire

Performance

YTD
-37.58%
-37.58%
1 Month
-30.29%
-30.29%
3 Month
-42.47%
-42.47%
6 Month
-63.27%
-63.27%
1 Year
-63.27%
-63.27%

More News

Read More
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Secures $600K in Funding for ENV205 Development
Via Investor Brand Network
Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
From Kairos Pharma, Ltd
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Adds Huntsman Cancer Institute to Phase 2 Trial for Prostate Cancer Therapy
Via Investor Brand Network
Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Preclinical Data on GITR Agonist KROS 101 at AACR-JCA Conference
Via Investor Brand Network
Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound’s Potential as a Therapeutic for Melanoma and Glioblastoma
From Kairos Pharma, Ltd.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Palantir Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why
Via Stocktwits
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present at AACR-JCA Joint Conference on Innovative Cancer Therapy
Via Investor Brand Network
Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024
From Kairos Pharma, Ltd
Via Business Wire
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) Highlights 2024 Milestones and 2025 Clinical Outlook
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Kairos, OS Therapies, AEON See Highest Weekly Spike In Retail Following Among Biotechs: Here's Why
Via Stocktwits
Exposures Product Safety
Kairos Pharma Provides Business Update and Outlook into 2025
From Kairos Pharma, Ltd
Via Business Wire
US Stocks Mixed; Nasdaq Down Over 1%
Via Benzinga
BioMedNewsBreaks — Kairos Pharma Ltd. (NYSE American: KAPA) to Present at Lytham Partners Investor Healthcare Summit
Via Investor Brand Network
Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit
From Kairos Pharma, Ltd
Via Business Wire
InvestorNewsBreaks – EF Hutton Provided ‘Buy’ Rating, $9.00 Price Target in Kairos Pharma, Ltd. (NYSE: KAPA) Recent Research Report
Via Investor Brand Network
BioMedNewsBreaks — Kairos Pharma, Ltd. (NYSE: KAPA) Receives ‘Buy’ Recommendation, $12.00 Price Target in Rodman & Renshaw Research Report
Via Investor Brand Network
Kairos Pharma to Participate in The Microcap Conference in January 2025
Via ACCESSWIRE
InvestorNewsBreaks – Kairos Pharma Ltd. (NYSE American: KAPA) to Present Growth Strategy at The Microcap Conference 2025
Via Investor Brand Network
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.